Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | DRD4 | P21917 | 4/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 5/20 | 0.50 |
| ▸ | HTR4 | Q13639 | 5/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060842 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL4171949 | 0.99 | CHRM1 (1.00) | DRD2CHRM1DRD4CHRM2CHRM4 | |
| SCHEMBL4500530 | 0.96 | CHRM1 (0.93) | DRD2CHRM1DRD4CHRM2CHRM4 | |
| SCHEMBL4499158 | 0.91 | DRD2 (0.83) | DRD2CHRM1DRD4CHRM2CHRM4 | |
| SCHEMBL4501134 | 0.88 | CHRM1 (0.79) | DRD2CHRM1DRD4CHRM2CHRM4 | |
| SCHEMBL4509346 | 0.88 | CHRM1 (0.79) | DRD2CHRM1DRD4CHRM2CHRM4 | |
| SCHEMBL4494582 | 0.88 | DRD2 (0.78) | DRD2CHRM1DRD4CHRM2CHRM4 | |
| SCHEMBL4497800 | 0.87 | CHRM1 (0.77) | DRD2CHRM1DRD4CHRM2CHRM4 | |
| SCHEMBL4509818 | 0.87 | CHRM1 (0.77) | DRD2CHRM1DRD4CHRM2CHRM4 | |
| SCHEMBL4489441 | 0.87 | DRD2 (0.77) | DRD2CHRM1DRD4CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-224287763-U | Display control circuit | SHENZHEN GUOHUA JIANYE ELECTRONIC TECHNOLOGY Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-118291542-A | Multi-gene deleted high-yield baculovirus expression vector Bac5.0s and application thereof | 华东理工大学 | 2024-07-05 | — | — | CN | claimed |
| CN-118272442-A | Multi-gene deleted high-yield baculovirus expression vector Bac4.0s and application thereof | 华东理工大学 | 2024-07-02 | — | — | CN | claimed |
| CN-118240882-A | Multi-gene deleted high-yield baculovirus expression vector Bac6.0s and application thereof | 华东理工大学 | 2024-06-25 | — | — | CN | claimed |
| US-11605980-B2 | Multi-transmitting multi-receiving magnetic-resonance wireless charging system for medium-power electronic apparatus | CHENGDU SPROUTING TECHNOLOGY CO., LTD. (CN) | 2023-03-14 | — | — | US | claimed |
| US-20220347170-A1 | Method of Reducing Brow Ache | LENZ THERAPEUTICS OPERATIONS, INC. | 2022-11-03 | — | — | US | claimed |
| WO-2022232205-A1 | A METHOD OF REDUCING BROW ACHE | LENZ THERAPEUTICS, INC. (US) | 2022-11-03 | — | — | WO | claimed |
| US-20180050008-A1 | OXYBUTYNIN TRANSDERMAL THERAPEUTIC SYSTEM MUSCARINIC AGONIST COMBINATION | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-02-22 | — | — | US | claimed |
| US-20260147006-A1 | SCREENING METHOD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-28 | — | — | US | disclosed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-224287763-U | Display control circuit | SHENZHEN GUOHUA JIANYE ELECTRONIC TECHNOLOGY Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20260143965-A1 | LIGHT EMITTING ELEMENT, AMINE COMPOUND FOR THE LIGHT EMITTING ELEMENT, AND DISPLAY DEVICE INCLUDING THE LIGHT EMITTING ELEMENT | SAMSUNG DISPLAY CO LTD (KR) | 2026-05-21 | — | — | US | disclosed |
| EP-3310336-B1 | OPHTHALMOLOGICAL COMPOSITION COMPRISING ACECLIDINE AND MANNITOL FOR USE IN THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260091068-A1 | METHODS FOR TREATING AND PREVENTING DISEASES | Tets, Viktor Veniaminovich (US) | 2026-04-02 | — | — | US | disclosed |
| US-20080108618-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | BRANN MARK | 2008-05-08 | — | — | US | disclosed |
| US-20030144285-A1 | Compounds with activity on muscarinic receptors | BRANN MARK (US) | 2003-07-31 | — | — | US | disclosed |
| US-6528529-B1 | 4-Methoxy-1-(4-(2-methylphenyl)-4-oxo-1-butyl)piperidine | ACADIA PHARMACEUTICALS INC. | 2003-03-04 | — | — | US | disclosed |
| WO-2001005763-A2 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-01-25 | — | — | WO | disclosed |
| EP-1068185-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | Acadia Pharmaceuticals Inc. (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050247-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | ACADIA PHARMACEUTICALS, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108618-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | CHRM3, CHRM2, CHRM1 | DRD2 470/4885CHRM1 3/4885DRD4 824/4885 |
| US-20260091068-A1 | METHODS FOR TREATING AND PREVENTING DISEASES | PRNP, FUCA1, SNCA | DRD2 3361/4885CHRM1 364/4885DRD4 3558/4885 |
| US-20030144285-A1 | Compounds with activity on muscarinic receptors | CHRM3, CHRM2, CHRM1 | DRD2 470/4885CHRM1 3/4885DRD4 824/4885 |
| US-20260143965-A1 | LIGHT EMITTING ELEMENT, AMINE COMPOUND FOR THE LIGHT EMITTING ELEMENT, AND DISPLAY DEVICE INCLUDING THE LIGHT EMITTING ELEMENT | NR2E3, NR2E1, NR0B2 | DRD2 40/4885CHRM1 33/4885DRD4 26/4885 |
| US-20260147006-A1 | SCREENING METHOD | CHRM1, CHRM4, CHRM5 | DRD2 420/4885CHRM1 1/4885DRD4 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.